World's #1 Anti-Wrinkle Cream

The speaker lays out the evidence for this protocol in detail. He references a landmark 2013 trial of 93 adults where daily sunscreen users showed no detectable skin aging after 4.5 years. A 2016 follow-up not only halted aging but demonstrated reversal of existing signs. He also points to a meta-analysis concluding that the highest-quality evidence indicates sunscreens prevent skin cancer. The mechanistic explanation covers visible light and UV radiation's effects: UV breaks down collagen and elastin, damages DNA, and overstimulates melanocytes, causing age spots. The sunscreen acts like a guard wall. The protocol is backed by a dramatic anecdotal photo: a 92-year-old who applied sunscreen to her face but not her neck for 40 years. The speaker frames this as the single most powerful anti-aging intervention, calling sunscreen 'the number one anti-aging cream.'

The speaker details the absorption problem: a 2020 study found all six tested active chemical sunscreen ingredients entered the bloodstream at levels exceeding the FDA's safety benchmarks. He stresses the study didn't prove harm, only absorption. However, he cites a 2017 review and a 2024 meta-analysis suggesting some ingredients may disrupt hormones and cause developmental issues, though the evidence is largely from animal studies at high doses. The FDA consequently requested more safety data on 12 common ingredients. The speaker interprets this uncertainty personally, opting to avoid those ingredients. He then presents mineral formulations as safe (zinc oxide and titanium dioxide are not absorbed) but acknowledges their aesthetic and water-resistance drawbacks. The protocol resolves the dilemma by adding a new class of chemical filters that are too large to penetrate skin, offering the elegance of chemical sunscreens without the absorption. He gives specific acceptable ingredient names and brands.

The transcript presents newer chemical sunscreen agents as a third way. Triazorb and beanol are introduced as examples of modern filters that are large enough to prevent skin penetration while still providing broad-spectrum UV protection and resisting degradation in sunlight. The speaker emphasizes that these compounds are already approved and in widespread use in the European Union and Australia, where regulators have been more proactive. He notes that they are 'potentially safer with much lower absorption rates' and 'have a broader range of UV coverage' than traditional options. The implication is that if you live in a jurisdiction where these are available, you can get high-protection sunscreens without the residue of minerals or the absorption risk of older chemicals.

The speaker presents this as essentially solving the sunscreen safety-versus-usability dilemma. He laments that the US FDA hasn't approved any new sunscreen ingredient since 1999, leaving Americans stuck with older formulas. However, he adds hopeful news: bermatresinol (Bemotrizinol) is currently under FDA review and has been thoroughly tested in other countries; approval is expected by the end of the year. The section frames a regulatory gap that has kept a superior generation of sunscreens out of reach for many consumers.

The speaker describes wrestling with the uncertainty around older chemical sunscreens. While acknowledging that the data don't prove harm, he states a personal decision: 'I don't want to be putting chemicals on my skin when I'm not sure what their long-term effects might be. This is particularly true when we've got some reasons to suspect that they're not good.' He then explains that living in New Zealand gives him access to sunscreens using newer, non-absorbing chemicals like bermatresinol, pointing to four Korean brands (the one he uses is Beauty of Joseon). For those without such access, he recommends CeraVe 100% Mineral Sunscreen SPF 50, which contains only zinc oxide and titanium dioxide and none of the FDA-flagged ingredients. He makes clear that this is his own risk calculus, not a universal directive, but the shift is clearly tied to the emerging data on absorption.

The speaker acknowledges the data points: sunscreen use in the US rose from 25% to 33% since 2000, while melanoma rates are climbing. He says the conclusion that sunscreen is useless is wrong. Instead, he offers three explanations. First, sunscreen users tend to stay in the sun longer because they feel protected, yet most apply too little, resulting in higher cumulative UV damage. Second, the population is getting older; peak melanoma diagnoses occur in the 70s, so an aging demographic alone pushes incidence numbers up. Third, he stresses that the causal chain—UV radiation causing skin cancer—is not in dispute, and properly used sunscreen greatly reduces UV exposure. The argument is that the observational trend is confounded, not that the intervention fails.